Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2026-02-25

FDA Approved: TAFLUPROST OPHTHALMIC — Supplemental Application (Prasco Laboratories)

View source ↗

Summary

FDA approved a supplemental application for tafluprost ophthalmic from Prasco Laboratories, enabling the marketing of a generic tafluprost ophthalmic solution. …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TAFLUPROST OPHTHALMIC (TAFLUPROST)

Snippet

SUPPL AP for TAFLUPROST OPHTHALMIC (TAFLUPROST)